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The peroxisome proliferator-activated receptors (PPAR’s) are members of the steroid/thyroid nuclear receptor, superfamily of
transcription factors. There are currently three known PPAR subtypes, α, β,a n dγ. The PPARs are now recognized participants in
a number of biological pathways some of which are implicated in the pathogenesis of age-related macular degeneration (AMD).
These include immune modulation, lipid regulation, and oxidant/antioxidant pathways important to the onset and progression
of “dry” AMD, and vascular endothelial growth factor (VEGF) mediated pathways that stimulate choroidal neovascularization
(CNV), characteristic of “wet” AMD. PPAR-α is found in retina and also on vascular cells important to formation of CNV. At
this time, however, relatively little is known about potential contributions of PPAR-α to the pathogenesis of dry and wet AMD.
This review examines current literature for potential roles of PPAR-α in the pathogenesis and potential treatment of AMD with
emphasis on prevention and treatment of wet AMD.
Copyright © 2008 M. del V Cano and P. L. Gehlbach. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Age-related macular degeneration (AMD) is the leading
cause of new blindness in the Western World and is cur-
rently responsible for more than half of all legal blindness in
the United States. There are approximately 8 million people
in the U.S. with early or intermediate stage AMD. Approx-
imately one million of these people will develop advanced
disease within the next ﬁve years [1–5]. Currently AMD is
estimated to aﬀect about 50 million people worldwide. With
aging of the population this number is expected to double by
the year 2020. Strategic approaches to management of AMD
include delaying onset and progression of nonneovascular
“(dry)” disease; preventing conversion from dry to wet dis-
ease and treatment of wet disease.
While speciﬁc antioxidant vitamin formulations are now
known to delay progression of intermediate disease, current
treatment of AMD focuses largely on providing therapeu-
tic intervention following the progression of intermediate
“(dry)” disease to late stage “(wet)” disease. The neovascu-
l a r( “ w e t ”o r“ e x u d a t i v e ” )f o r mo fA M Dc a nl e a dt or a p i d
visual decline and accounts for nearly 90% of vision lost.
It is characterized by development of pathologic choroidal
neovascularization (CNV). Early strategies to ablate CNV
used thermal laser or photodynamic therapy. These are now
less frequently used as treatments that antagonize the eﬀects
of vascular endothelial growth factor (VEGF), continue to
enhance eﬃcacy, and improve outcomes. Currently pegap-
tanib, ranibizumab, and bevacizumab are considered rela-
tively safe and achieve therapeutic eﬀects that may include
inhibition/regressionofCNV,decreasedvascularleakage,ab-
sorption of subretinal ﬂuid, and improved vision [6–10].
The peroxisome proliferator-activated receptors (PPAR’s)
are not, at the present time, known as direct treatment
targets in the management of AMD. Each represents a sep-
arate nuclear receptor of the steroid super-family of ligand
activated transcription factors that induce steroid hormones,
thyroid hormones, vitamin D, and retinoid acid receptor
[11]. PPAR’s comprise a family of three ligand-activated
transcription factors (α, β,a n dγ) that are characterized by
distinct function, ligand speciﬁcity, and tissue distribution.
The PPAR transcription factors regulate transcription of
many genes involved in diﬀerentiation, proliferation, and
apoptosis, in a variety of cell types. During gene expression
the PPAR forms a heterodimer receptor complex with
the 9-cis-retinoic acid receptor (RXR). The PPAR/RXR2 PPAR Research
heterodimer is associated with a multiprotein corepressor.
When a ligand or agonist binds to the receptor, the core-
pressor complex dissociates. The heterodimer receptor then
binds with peroxisome proliferator response elements on the
promoter domain of target genes to stimulate transcription
[12].
Three distinct PPAR’s had been identiﬁed in mammals,
PPAR-α,P P A R - γ, and PPAR-δ (also referred to as PPAR β).
The ﬁrst PPAR entity identiﬁed was PPAR-α agonist, which
has multiple functions that result in an improved lipid pro-
ﬁle,increasinghighdensitylipoproteincholesterol(HDL-C),
decreasing triglycerides and free fatty acids, and shifting low
density lipoprotein cholesterol (LDL-C) to larger less athero-
genic particles. Each of these improvements in the lipid pro-
ﬁle is potentially beneﬁcial and may in theory lead to delay
in AMD onset and progression thereby avoiding late stage or
“wet” disease.
PPAR-α is transcribed from chromosome 22q12-13.1, is
primarily expressed in tissues with elevated mitochondrial
and peroxisomal fatty acids β-oxidation rates, such as liver,
heart muscle, kidney, skeletal muscle, retina, and brown fat
[13–15]andmayhaveapotential rolein oxidant/antioxidant
pathways now strongly implicated in the pathogenesis of dry
AMD. PPAR-α is also present in cells of the arterial wall as-
sociated with smooth muscle cells [16] and endothelial cells
[17] and is found in monocytes and macrophages [18] that
participate in CNV formation, characteristic of wet AMD
[19]. The PPAR’s are activated by a number of ligands in-
cluding eicosanoids and fatty acids. In addition, synthetic
antidiabetic and lipid lowering ﬁbrates have been shown to
activate PPAR-γ and PPAR-α, respectively. PPAR-α is the
maintargetofﬁbratedrugs,aclassofamphipathiccarboxylic
acids (gemﬁbrozil, fenoﬁbrate, cloﬁbrate) used in managing
elevated triglycerides and cholesterol. PPAR-γ is highly ex-
pressed in adipose tissues and is a key mediator of adipoge-
nesis [20, 21] and glucose homeostasis [22]. Little is known
about the PPAR-δ which is expressed ubiquitously and has
now been linked to obesity.
2. PPARs IN THE VASCULATURE
In addition to well established roles for the PPAR’s in
metabolic pathways, recent work suggests that the PPAR’s
may be involved in vascular regulation. Several groups
have identiﬁed PPAR-γ and PPAR-α expression in mono-
cytes/macrophages, vascular smooth muscle cells, and en-
dothelial cells [16–18]. In the endothelium, PPAR-γ has been
identiﬁed by PCR reaction [23], western blot and immuno-
precipitation. PPAR-α has been demonstrated in the vascu-
lar endothelium by immunohistochemical technique [24].
While PPAR-γ has been widely studied for its antiangiogenic
properties[25],recentstudiesnowindicatethatPPAR-αmay
have antiangiogenic properties as well [26, 27], a ﬁnding
with potential therapeutic implications for wet AMD. PPAR-
α agonists have recently been shown to inhibit expression of
VEGF receptor 2 (VEGFR2) upregulation in neovasculariza-
tion [26]. Varet et al. have demonstrated that fenoﬁbrate, a
PPAR-α ligand, inhibits angiogenesis in vitro and in vivo.
They have also shown that fenoﬁbrate reduces endothelial
cell growth rate, endothelial cell mediated wound repair, and
capillary tube formation. Interestingly fenoﬁbrate has been
showntoinhibitbFGF-inducedangiogenesisinvivo[27].Si-
multaneous inhibition of VEGFR2, bFGF, and VEGF would
in theory have a profound eﬀect on pathological angiogene-
sis in the eye.
PPAR-α and PPAR-γ are associated with anti-inﬂamma-
tory and antioxidant activity [28–30] and have antiathero-
genic eﬀects [31]. Each of these pathways is considered im-
portanttotheonsetandprogressionofearlyAMDandtode-
velopmentoflatechoroidalneovascularization.PPAR-αacti-
vators inhibit expression of vascular cell adhesion molecules
on the endothelium that are important for the development
of new blood vessels and for atherogenesis [32]. Experimen-
talevidencesuggeststhatthePPARactivatorspreventinvitro
vascular muscle cell growth [33], limit inﬂammatory re-
sponses[16],andareproapoptoticindicatingapotentialrole
in vascular remodeling [34]. Such activity could theoretically
inhibit thetransitionfromdry towetAMD.PPAR-αagonists
alsoinhibitinterleukin-1-inducedproductionofinterleukin-
6 and prostaglandins [16]. Moreover, Delerive et al. have
demonstrated prolonged inﬂammatory responses and in-
creased interleukin-6 production in aortic explants of PPAR-
α deﬁcient mice [35] underscoring the anti-inﬂammatory
potential of PPAR-α.
3. PPAR-α IN ANGIOGENESIS
Pathological angiogenesis leading to choroidal neovascular-
ization is pathognomonic of “wet” AMD. Angiogenesis is the
formation of new blood vessels from preexisting vessels and
involves endothelial cell proliferation, migration, and orga-
nization into new capillary tubes. Pathological angiogenesis
isintegraltoanumberofprevalentoculardiseasescharacter-
izedbythedevelopmentofocularneovascularizationinclud-
ingbutnotlimitedtowetAMD,diabeticretinopathy,corneal
neovascularization, the occlusive retinal vasculopathies, and
retinopathy of prematurity. Inhibitors of ocular angiogene-
sis therefore have broad therapeutic implications for patients
with these diseases.
Varet et al. demonstrated inhibition of angiogenesis
by the PPAR-α ligand fenoﬁbrate [27]. The antiangiogenic
properties exhibited were characterized by a dose-dependent
decrease in endothelial cell proliferation and apoptosis.
Fenoﬁbrates also reduced endothelial cell migration in vitro
and capillary tube formation in a matrigel assay. Meissner
et al. have also reported a reduction in endothelial cell prolif-
eration, migration, and tube formation following treatment
with fenoﬁbrates and also with the PPAR-α agonist Wy14643
[26]. In further support of the evident antiangiogenic eﬀect
is the observation that several PPAR-α agonists decrease ex-
pression of VEGF receptor 2 (VEGFR2) in human umbilical
endothelial cells (HUVECs) [26].
VEGFR2isthemostpotentoftheVEGFreceptors.When
activated VEGFR2 initiates signaling that leads to endothe-
lial cell proliferation and also to expression of cytoprotective
antiapoptotic molecules [36]. VEGFR2 is detectable only at
relatively low levels in the adult vasculature; it is markedly
up regulated by blood vessels during chronic inﬂammation,M .d e lVC a n oa n dP .L .G e h l b a c h 3
hypoxia, tumor growth, and wound repair. VEGFR2 and
VEGF expression both increase as part of the angiogenic re-
sponse and this coordinate response is observed in wet AMD
as well as other ocular diseases characterized by pathological
neovascularization [37, 38]. VEGF has been identiﬁed in ﬁ-
broblastic cells and transdiﬀerentiated RPE cells in surgically
excised choroidal neovascular membranes (CNV) [39, 40].
VEGF expression is also increased in macular RPE cells in
patients with AMD [41]. Vitreous VEGF levels are signiﬁ-
cantly higher in AMD patients with CNV as compared to
healthy controls [42]. VEGF production is also increased in
RPE cells, retinal vascular endothelial cells, retinal pericytes
[43–45], and Muller cells [46]. The endothelial cells of the
retinal vasculature possess numerous high-aﬃnity VEGF re-
ceptors.
PPAR-α agonists have been associated with a reduction
in VEGF levels in OVCAR-3 tumor as well as in DISS-
derived ascites [47]. They also reduce microvessel density
in these tumors. Other studies have similarly demonstrated
that a reduction in PPAR-α message and activity is associ-
ated with hypoxia [48]. Hypoxia-induced VEGF expression
contributes to choroidal and retinal neovascularization. The
relative signiﬁcance of the eﬀect of PPAR-α on VEGFR2 and
VEGF expression in the setting of AMD is not yet known.
4. PPAR-α AND WET AMD
Fenoﬁbrates and other PPAR-α agonists are reported to de-
crease expression of VEGF and VEGFR2 that are central to
theVEGF/VEGFRsignalingcascadeandimportanttothede-
velopment of pathological CNV in AMD. Growth of exper-
imentally induced CNV, via laser rupture of Bruch’s mem-
brane in a rat model, is inhibited by intravitreous treatment
with a PPAR-γ agonist [49]. At the time of this writing, simi-
lar data has not been reported for PPAR-α. Evaluation of this
questionishoweversupportedbyevidenceofPPAR-αreduc-
tion of VEGFR2 expression in endothelial cells [26]a n dr e -
ported decreases in tissue VEGF levels [47]. PPAR-α activa-
tors have also been shown to limit the expression of vascu-
lar cell adhesion molecules in the endothelium, an early step
in atherogenesis and an important step in the development
of new blood vessels [32]. Inhibition of CNV initiation and
early progression of CNV are therefore theoretical beneﬁts
of PPAR-α agonist treatment. Described proapoptotic eﬀects
also suggest therapeutic roles in early CNV development or
late regression of CNV [34].
With reports that the PPAR’s limit inﬂammatory as well
as oxidative responses and improve lipid proﬁles [16, 28,
29, 35, 37, 50], it is tempting to speculate on a potential
role in delaying onset and progression of nonneovascular
“(dry)” disease, thereby potentially preventing latter “wet”
stages of disease. There is a substantial literature linking ox-
idativedamagetodryAMDpathogenesis[51].PPAR-αcould
theoretically inhibit AMD progression via eﬀects on oxida-
tive pathways. It has been previously reported that PPAR-α
activation induces the expression and activation of antioxi-
dantenzymes,suchassuperoxidedismutaseandglutathione
peroxidase [29]. It has also been reported that PPAR-α ago-
nists are neuroprotective in the CNS, and that this neuropro-
tection has been associated with a decrease in cerebral oxida-
tive stress.Consumption ofdirectactingantioxidants topro-
vide protection to the retina and the RPE is supported by the
AREDS clinical trial that has added antioxidant formulation
to the routine care of dry AMD. Whether the antioxidant ef-
fectsofPPAR-αactivationarecomparabletothoseofAREDS
formulation is not known.
Because fenoﬁbrates are orally administered and have an
established safety proﬁle in the treatment of atherosclerosis,
investigations pertaining to the impact oforal therapy onox-
idative stress, VEFGR2, VEGF, and CNV growth are impor-
tant. It is also important to consider examining for poten-
tial beneﬁcial eﬀects on onset and progression of nonneo-
vascular “(dry)” disease and conversion from dry to wet dis-
ease. These and other factors support a hypothesis that asks
whether PPAR-α may play a therapeutic role in either pre-
vention or treatment of wet AMD.
5. SUMMARY
AMD remains the leading cause of new blindness in people
over 65 years of age and is the leading cause of new blindness
in the Western World. The conversion of dry AMD to wet
AMD is associated with most of the attendant visual decline.
Currently a variety of antiangiogenic treatments directed at
halting CNV growth and leakage are the mainstay of therapy.
The most frequently injected agent ranibizumab (Lucentis)
results in stabilization of visual acuity at the pretreatment
level for a majority of patients and results in improvement of
visual acuity by 3 or more lines in about 1/3 of those treated.
The therapy does not however restore visual acuity to nor-
mal levels in the majority of those treated. Moreover, ther-
apy with ranibizumab and other currently available VEGF
antagonists requires frequent intravitreous injections and is
associated with signiﬁcant expense, some risk, and for most,
incomplete recovery of vision.
An oral therapy with an established safety proﬁle that
favorably modiﬁed VEGF/VEGFR signaling and increased
the antioxidant capacity could signiﬁcantly impact the ther-
apy of wet AMD. Taken collectively, the PPAR’s demonstrate
favorable biological activity in pathophysiological pathways
relevant to the onset and progression of nonneovascular
and neovascular age-related macular degeneration. The rel-
ative importance of the PPAR-α pathway in AMD is not yet
known. There is, however, suﬃcient preliminary evidence to
support further study of a potential role for PPAR-α pathway
modulation as an adjuvant or primary treatment in AMD.
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